前列腺癌中丝氨酸苏氨酸激酶-1和驱动蛋白-5蛋白表达及相关性研究

Expression and correlation of PIM-1 and Eg5 proteins in prostate cancer

目的:检测前列腺癌中丝氨酸苏氨酸激酶-1(PIM-1)和驱动蛋白-5(Eg5)蛋白表达,探讨其表达与前列腺癌临床病理及它们之间的相关性。方法:采用免疫组化SP法检测81例前列腺癌和43例前列腺增生组织中PIM-1和Eg5蛋白表达水平,卡方检验分析PIM-1和Eg5蛋白表达阳性率与前列腺癌的临床病理特征之间的关系,采用Spearman相关分析PIM-1与Eg5蛋白在前列腺癌中的相关性。结果:PIM-1和Eg5蛋白在前列腺癌中表达增高,明显高于前列腺增生,差异有统计学意义(P<0.05),PIM-1和Eg5蛋白表达阳性率与Gleason评分、临床分期、术前PSA和5年生化复发有关(P<0.05);与患者年龄无关(P>0.05)。PIM-1和Eg5蛋白表达阳性率高的生化复发率高于PIM-1和Eg5蛋白表达阳性率低的患者(P<0.05),相关性分析显示,前列腺癌中PIM-1和Eg5蛋白呈正相关(r=0.825,P<0.05)。结论:PIM-1和Eg5基因可能与前列腺癌演化和进展有关,二者联合检测有望提高对前列腺癌的预测能力。

Objective To detect the expression of serine threonine kinase-1(PIM-1)and kinesin-5(Eg5)proteins in prostate cancer and to investigate their correlation with the clinicopathology of prostate cancer.Methods The expression of PIM-1 and Eg5 protein in 81 cases of prostate cancer and 43 cases of benign prostatic hyperplasia were detected by immunohistochemical streptavidin-perosidase method.The relationship between the positive rate of PIM-1 and Eg5 protein expression and the clinicopathological characteristics of prostate cancer were analyzed by chi square test.The correlation between PIM-1 and Eg5 protein in prostate cancer was evaluated by Pearson correlation analysis.Results The expressions of PIM-1 and Eg5 proteins in prostate cancer were significantly higher than those in benign prostatic hyperplasia(P<0.05).The positive rates of PIM-1 and Eg5 protein expressions were related to Gleason score,clinical stage,preoperative PSA and 5-year biochemical recurrence(P<0.05).They were not related to the patient's age(P>0.05).Biochemical relapse with high positive rate of PIM-1 and Eg5 protein expression was higher than that with low positive rate of PIM-1 and Eg5 protein expression(P<0.05).Pearson correlation analysis showed that PIM-1 and Eg5 proteins were positively correlated in prostate cancer(r=0.825,P<0.05).Conclusions PIM-1 and Eg5 genes may be related to the evolution and progression of prostate cancer,and joint detection may improve the prediction of prostate cancer.